In vitro test to confirm diagnosis of allopurinol‐induced severe cutaneous adverse reactions

Allopurinol is a frequent cause of severe cutaneous adverse reactions (SCARs), such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The reactions can potentially be fatal. As drug rechallenge in patients with a history of drug‐induced SCARs is contraindicated, in vitro testing may have a diagnostic role as a confirmation test.

[1]  Wei-Chi Wang,et al.  Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. , 2015, The Journal of investigative dermatology.

[2]  R. Day,et al.  Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin , 2014, Annals of the rheumatic diseases.

[3]  Min-Hye Kim,et al.  Lamotrigine-induced toxic epidermal necrolysis confirmed by in vitro granulysin and cytokine assays , 2014, Asia Pacific allergy.

[4]  M. Mockenhaupt,et al.  Mechanisms that limit proliferative potential of drug-specific LTT in drug-induced severe cutaneous adverse reaction patients , 2014, Clinical and Translational Allergy.

[5]  C. Riccardi,et al.  GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. , 2014, Cell reports.

[6]  Andrew Gibson,et al.  Negative Regulation by PD-L1 during Drug-Specific Priming of IL-22–Secreting T Cells and the Influence of PD-1 on Effector T Cell Function , 2014, The Journal of Immunology.

[7]  C. Largiadèr,et al.  Allopurinol hypersensitivity is primarily mediated by dose‐dependent oxypurinol‐specific T cell response , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  E. Gianchecchi,et al.  Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. , 2013, Autoimmunity reviews.

[9]  D. Margolis,et al.  Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population‐Based Cohort Study , 2013, Arthritis care & research.

[10]  E. Healy,et al.  In vitro diagnostic assays are effective during the acute phase of delayed‐type drug hypersensitivity reactions , 2013, The British journal of dermatology.

[11]  J. Klaewsongkram,et al.  The potential of using enzyme-linked immunospot to diagnose cephalosporin-induced maculopapular exanthems. , 2013, Acta dermato-venereologica.

[12]  P. López,et al.  Effects of glucocorticoid treatment on CD25⁻FOXP3⁺ population and cytokine-producing cells in rheumatoid arthritis. , 2012, Rheumatology.

[13]  A. Dunant,et al.  ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.

[14]  M. Gonçalo,et al.  Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS) , 2010, Contact dermatitis.

[15]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[16]  T. Shiohara,et al.  Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome1 , 2009, The Journal of Immunology.

[17]  F. Bérard,et al.  Detection and quantification of drug‐specific T cells in penicillin allergy , 2009, Allergy.

[18]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[19]  T. Shiohara,et al.  Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption , 2007, Allergy.

[20]  P. Demoly,et al.  Variability in the clinical pattern of cutaneous side‐effects of drugs with systemic symptoms: does a DRESS syndrome really exist? , 2006, The British journal of dermatology.

[21]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Pichler,et al.  The lymphocyte transformation test in the diagnosis of drug hypersensitivity , 2004, Allergy.

[23]  A. Kappeler,et al.  T cell involvement in cutaneous drug eruptions , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.